Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Select a Mutual Fund
Risk | Very High | - |
Rating | 2.0 | - |
Min SIP Amount | ₹100 | - |
Expense Ratio | 2.33 | - |
NAV | ₹29.58 | - |
Fund Started | 20 Jun 2019 | - |
Fund Size | ₹890.33 Cr | - |
Exit Load | Exit load of 1% if redeemed within 30 days. | - |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 16.49% | - |
3 Year | 17.00% | - |
5 Year | 21.43% | - |
1 Year
3 Year
5 Year
Equity | 96.51% | - |
Cash | 3.49% | - |
Equity
Cash
Top 10 Holdings |
| - |
Top 10 Holdings
Name | Assets |
---|---|
Sun Pharmaceutical Industries Ltd. | 14.54% |
Cipla Ltd. | 8.62% |
Torrent Pharmaceuticals Ltd. | 8.10% |
Apollo Hospitals Enterprise Ltd. | 6.06% |
Lupin Ltd. | 5.19% |
Aurobindo Pharma Ltd. | 5.12% |
Fortis Healthcare Ltd. | 4.27% |
Ajanta Pharma Ltd. | 4.26% |
Ipca Laboratories Ltd. | 4.19% |
Alkem Laboratories Ltd. | 3.15% |
Name | Dhaval Joshi | - |
Start Date | 21 Nov 2022 | - |
Name
Start Date
Description | The scheme seeks to provides long term capital appreciation by investing in equity/equity related instruments of the companies in the Pharmaceuticals, Healthcare and Allied sectors in India. | - |
Launch Date | 20 Jun 2019 | - |
Description
Launch Date